Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Genentech 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Genentech 4Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genentech

4Q Revenues: $3.7 billion (+25%)

4Q Earnings: $931 million (+14%)

FY Revenues: $13.4 billion (+14%)

FY Earnings: $3.4 billion (+24%)

Comments: U.S. product sales were $2.5 million in the quarter (+13%) and up 11% to $9.5 million for the year. Avastin sales were $731 million in the quarter (+21%) and $2.7 billion for the year (+17%). Rituxan sales were $677 million in the quarter (+14%) and $2.6 billion for the year (+13%). Herceptin sales were $337 million in the quarter (+3%) and up 7% to $1.4 billion for the year. Lucentis sales were up 20% in the quarter to $236 million, and up 7% for the year to $875 million. R&D expenses were $757 million in the quarter (+22%) and $2.6 billion for the year (+15%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters